BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 28521680)

  • 1. Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis.
    Vergani L
    Curr Med Chem; 2019; 26(19):3439-3456. PubMed ID: 28521680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD.
    Mashek DG
    Mol Metab; 2021 Aug; 50():101115. PubMed ID: 33186758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease.
    Liu W; Baker SS; Baker RD; Zhu L
    Curr Drug Targets; 2015; 16(12):1301-14. PubMed ID: 25915484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
    Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
    FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.
    Alamri H; Patterson NH; Yang E; Zoroquiain P; Lazaris A; Chaurand P; Metrakos P
    Anal Bioanal Chem; 2019 Feb; 411(4):885-894. PubMed ID: 30515538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomechanics of cultured hepatic cells during different steatogenic hits.
    Baldini F; Bartolozzi A; Ardito M; Voci A; Portincasa P; Vassalli M; Vergani L
    J Mech Behav Biomed Mater; 2019 Sep; 97():296-305. PubMed ID: 31151002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models of non-Alcoholic Fatty Liver Disease and Potential Translational Value: the Effects of 3,5-L-diiodothyronine.
    Grasselli E; Canesi L; Portincasa P; Voci A; Vergani L; Demori I
    Ann Hepatol; 2017; 16(5):707-719. PubMed ID: 28809727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.
    Mato JM; Alonso C; Noureddin M; Lu SC
    World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of hepatic fatty acids during non-alcoholic steatohepatitis progression using magnetic resonance spectroscopy.
    Xavier A; Zacconi F; Santana-Romo F; Eykyn TR; Lavin B; Phinikaridou A; Botnar R; Uribe S; Oyarzún JE; Cabrera D; Arrese M; Andia ME
    Ann Hepatol; 2021; 25():100358. PubMed ID: 33962045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.
    Ipsen DH; Lykkesfeldt J; Tveden-Nyborg P
    Cell Mol Life Sci; 2018 Sep; 75(18):3313-3327. PubMed ID: 29936596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human germline hedgehog pathway mutations predispose to fatty liver.
    Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
    J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
    Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Potential of the FSP1cre-
    Chen J; Zhuang Y; Sng MK; Tan NS; Wahli W
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31618976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD.
    Huang KT; Chen KD; Hsu LW; Kung CP; Li SR; Chen CC; Chiu KW; Goto S; Chen CL
    Nutrients; 2020 Jan; 12(1):. PubMed ID: 31968655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.